Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
180 hedge funds and large institutions have $1.92B invested in Portola Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 51 increasing their positions, 49 reducing their positions, and 14 closing their positions.
271% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 14
104% more call options, than puts
Call options by funds: $39.4M | Put options by funds: $19.4M
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
73% more capital invested
Capital invested by funds: $1.11B → $1.92B (+$810M)
20% more funds holding
Funds holding: 150 → 180 (+30)
4% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$128M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$35.5M |
| 3 |
CCM
Cadian Capital Management
New York
|
+$27.7M |
| 4 |
FAM
Fred Alger Management
New York
|
+$23.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$102M |
| 2 |
Millennium Management
New York
|
-$27.9M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$26M |
| 4 |
Morgan Stanley
New York
|
-$18M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$12.6M |
PTLA Hedge Fund Activity: Q1 2017 in Review
180 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q1 2017, worth a combined $1.92B — up 73% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new PTLA positions and 14 closed out — a net gain of 38 holders — while 51 added to existing stakes and 49 trimmed.
The largest buyer was BlackRock, adding an estimated $128M. The largest seller was Deerfield Management, cutting an estimated $102M.
- 180 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q1 2017, up from 150 in Q4 2016.
- Funds reported $1.92B of Portola Pharmaceuticals, Inc. stock for Q1 2017, up 73% quarter-over-quarter.
- 52 funds opened new Portola Pharmaceuticals, Inc. positions in Q1 2017 and 14 closed out, a net change of +38 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $128M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q1 2017 was Deerfield Management, an estimated $102M sold.
Based on aggregated 13F filings for Q1 2017.